All In Biotech

Drug Trial Radar · NCT05006716

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 689 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

689

Planned (sponsor's estimate)

Start

Sep 13, 2021

Primary completion

Mar 2027

Study completion Mar 2030

Sponsor

Lead sponsor
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
First posted
Aug 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Conditions

  • B-cell Malignancy
  • Marginal Zone Lymphoma
  • Follicular Lymphoma
  • Non-Hodgkin Lymphoma
  • Waldenström Macroglobulinemia
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Mantle Cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Richter Transformation

Interventions

  • TacabrutidegDrug

    Orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants with Adverse Events (AEs)Time frame: From the first dose of tacabrutideg until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (Up to 47 weeks)
  2. Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of TacabrutidegTime frame: Approximately 28 days
  3. Phase 1: Recommended dose(s) for Expansion (RDFE) of tacabrutidegTime frame: Approximately 3 years
  4. Phase 2: Overall response rate (ORR)Time frame: approximately 3 years

Locations

114 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama At Birmingham Hospital

    Birmingham, Alabama · Recruiting

  • Mayo Clinic Phoenix

    Phoenix, Arizona · Completed

  • Honor Health Research Institute

    Scottsdale, Arizona · Recruiting

  • University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • University of California San Diego (Ucsd) Moores Cancer Center

    La Jolla, California · Recruiting

  • Stanford Medicine

    Palo Alto, California · Recruiting

  • UCLA Santa Monica Cancer Care

    Santa Monica, California · Recruiting

  • Uchealth North

    Fort Collins, Colorado · Recruiting

  • Mayo Clinic Jacksonville

    Jacksonville, Florida · Recruiting

  • Mount Sinai Medical Center Braman Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • Tampa General Hospital Cancer Institute

    Tampa, Florida · Recruiting

  • Augusta University

    Augusta, Georgia · Recruiting

  • Southeastern Regional Medical Center

    Newnan, Georgia · Recruiting

  • Midwestern Regional Medical Center

    Zion, Illinois · Completed

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Norton Cancer Institute Pavilion

    Louisville, Kentucky · Active not recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • American Oncology Partners of Maryland Pa

    Bethesda, Maryland · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • Weill Cornell Medical College Newyork Presbyterian Hospital

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center Mskcc

    New York, New York · Recruiting

  • Tennesse Oncology Chattanooga Downtown

    Chattanooga, Tennessee · Recruiting

  • Tennessee Oncology, Pllc Nashville

    Nashville, Tennessee · Recruiting

  • Md Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Commonwealth University Massey Cancer Center

    Richmond, Virginia · Recruiting

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington · Recruiting

  • Concord Repatriation General Hospital

    Concord, New South Wales, Australia · Recruiting

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia · Recruiting

  • St Vincents Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • Austin Health

    Heidelberg, Victoria, Australia · Recruiting

  • Peter Maccallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Perth Blood Institute

    West Perth, Western Australia, Australia · Recruiting

Showing 40 of 114 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.